|
Recent Developments |
|
06-JUL-15
Transgene Biotek, one of Biotechnology companies in India, announced today that its novel molecule miRNA 101 for therapy against liver cancer has been allowed for issuance of a USA patent after the prosecutions on the merits have been closed
23-JAN-13
Transgene Biotek has entered into a definitive licensing and technology transfer agreement with Atral Cipan of Portugal.
23-NOV-11
Transgene Biotek today announced that the management ... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Mar-2015(12) | 31-Mar-2014 (12) | 31-Mar-2013 (12) | | Net sales | 3.32 | 9.81 | 150.31 | | Other Income | 0.00 | 8.00 | 0.60 | | Total Income | 3.32 | 17.81 | 150.91 | | Cost of goods sold | 20.38 | 25.49 | 158.67 | | OPBDIT | -17.06 | -7.68 | -7.76 | | PAT | -192.10 | -179.85 | -19.89 | | Gross Block | - | - | - | | Equity capital | 757.70 | 757.70 | 657.70 | | EPS (Rs.) | - | -2.37 | -0.30 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | NA | NA | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | -513.9 | -43.1 | -5.1 | | Net margin (% of OI) | -5786.1 | -1009.8 | -13.2 |
|
|
Detailed Financials
|
|
|
|
|
